Allanyheter.comVeckans nyhetsnotiser

Hansa Biopharma divests its equity holding in Genovis

Proceeds to be used to further expedite development of Company’s pipeline Lund, Sweden, April 15, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that it has divested its entire equity stake in Genovis AB (NASDAQ Stockholm: GENO).

Taggar: hansa, biopharma, divests

Läs hela artikeln på Dagens industri